<?xml version='1.0' encoding='UTF-8'?>
<rss xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" version="2.0"><channel><title>Oncology</title><link>https://nrouizem.github.io/test/oncology_feed.xml</link><description>Daily curated &amp; summarized biopharma news.</description><atom:link href="https://nrouizem.github.io/test/oncology_feed.xml" rel="self"/><docs>http://www.rssboard.org/rss-specification</docs><generator>python-feedgen</generator><language>en</language><lastBuildDate>Thu, 13 Mar 2025 00:37:40 +0000</lastBuildDate><item><title>AstraZeneca Builds Stomach Cancer Case for Imfinzi With Strong Phase III Data</title><link>https://www.biospace.com/drug-development/astrazeneca-builds-stomach-cancer-case-for-imfinzi-with-strong-phase-iii-data</link><description>AstraZeneca's cancer drug Imfinzi is poised to drive significant growth in 2025, with regulators set to decide on its expanded use in treating stomach and bladder cancers. The blockbuster therapy generated over $4.7 billion in sales last year, cementing its role as a key revenue driver for the pharmaceutical giant.</description><pubDate>Fri, 07 Mar 2025 13:58:56 +0000</pubDate></item><item><title>Multi-Modality Testing of EGFR</title><link>https://www.fiercebiotech.com/resource/multi-modality-testing-egfr</link><description>Neogenomics highlights its new white paper advocating a multi-modality testing approach to improve clinical trials, offering deeper insights into patient responses and treatment effectiveness. The sponsored resource, available for download, underscores how integrating diverse testing methods can advance oncology research and therapeutic outcomes.</description><pubDate>Fri, 07 Mar 2025 18:04:58 +0000</pubDate></item><item><title>Sun Pharma to acquire Checkpoint Therapeutics and its anti-PD-L1 antibody</title><link>https://endpts.com/sun-pharma-to-acquire-checkpoint-therapeutics-and-its-anti-pd-l1-antibody/</link><description>Checkpoint Therapeutics has pivoted from seeking a partnership for its newly approved cancer drug to being acquired outright by India’s Sun Pharma in a strategic immuno-oncology expansion. The deal, valued at $4.10 per share, marks a swift exit for Checkpoint and reinforces Sun Pharma’s growing footprint in cutting-edge cancer therapies.</description><pubDate>Mon, 10 Mar 2025 12:20:53 +0000</pubDate></item><item><title>BioNTech's shares dip after posting lukewarm revenue guidance</title><link>https://endpts.com/biontechs-shares-dip-after-posting-lukewarm-revenue-guidance/</link><description>BioNTech shares fell 2% after projecting lower 2025 revenues, citing reduced COVID-19 vaccine demand and oversupply challenges despite a solid $4.2 billion revenue in 2023. The company plans to pivot toward advancing cancer treatments and cost-cutting measures while preparing for new vaccine launches to offset declining pandemic-related sales.</description><pubDate>Mon, 10 Mar 2025 19:37:01 +0000</pubDate></item><item><title>Making Just-in-Time Oncology Trials Work: Overcoming Barriers and Unlocking Potential</title><link>https://www.fiercebiotech.com/premium/webinar/1368918</link><description>Just-in-time (JIT) oncology trials aim to accelerate research and improve patient access by activating trial sites only after identifying eligible patients, requiring strong collaboration between sponsors, sites, and IRBs to streamline processes and pre-negotiate agreements. An upcoming webinar will explore strategies like data-driven prescreening, standardized protocols, and centralized oversight to overcome operational barriers and expand the use of JIT trials in delivering faster, cost-effective cancer treatments.</description><pubDate>Mon, 10 Mar 2025 19:50:06 +0000</pubDate></item><item><title>Bristol Myers buys out cell therapy partner 2seventy bio</title><link>https://endpts.com/bristol-myers-buys-out-cell-therapy-partner-2seventy-bio/</link><description>Bristol Myers Squibb has agreed to acquire 2seventy bio, its longtime partner in developing the CAR-T cell therapy Abecma for multiple myeloma, in a $286 million all-cash deal. The acquisition strengthens Bristol Myers' foothold in cancer therapies, building on the companies' existing collaboration aimed at advancing cutting-edge immunocellular treatments.</description><pubDate>Tue, 11 Mar 2025 08:13:39 +0000</pubDate></item><item><title>Arvinas and Pfizer’s PROTAC vepdegestrant works in subset of breast cancer patients</title><link>https://endpts.com/arvinas-and-pfizers-protac-vepdegestrant-works-in-subset-of-breast-cancer-patients/</link><description>Arvinas and Pfizer's partnered experimental breast cancer drug, vepdegestrant, failed to outperform existing therapies in the Phase 3 VERITAC-2 trial, casting doubt on its competitive potential. The results highlight challenges for the collaboration’s aim to deliver a differentiated treatment in the crowded protein degrader landscape.</description><pubDate>Tue, 11 Mar 2025 11:56:49 +0000</pubDate></item><item><title>Pfizer, Arvinas Post Mixed Late-Stage Breast Cancer Data for Closely Watched PROTAC Drug</title><link>https://www.biospace.com/drug-development/pfizer-arvinas-post-mixed-late-stage-breast-cancer-data-for-closely-watched-protac-drug</link><description>Vepdegestrant’s mixed trial results—stalling on broad progression-free survival but showing promise in a niche patient group—sparked a 43% plunge in Arvinas’ stock, with analysts casting doubt on the drug's long-term viability. While no new deals were announced, the setback raises questions about the company’s ability to attract future partnerships or advance the drug’s commercial prospects.</description><pubDate>Tue, 11 Mar 2025 14:08:28 +0000</pubDate></item><item><title>Corrected: Merck opens billion-dollar US facility to make Gardasil</title><link>https://endpts.com/merck-opens-billion-dollar-facility-to-make-bladder-cancer-immunotherapy/</link><description>Merck has launched a new North Carolina-based manufacturing facility to produce HPV vaccines, including Gardasil and Gardasil 9, to meet rising global demand for cervical cancer prevention. The plant’s opening aligns with Merck’s strategy to expand production capacity amid increasing vaccine rollout efforts worldwide.</description><pubDate>Tue, 11 Mar 2025 14:50:06 +0000</pubDate></item><item><title>Arvinas gets positive breast cancer data, but finds differentiation a hard sell</title><link>https://www.biopharmadive.com/news/arvinas-pfizer-vepdegestrant-breast-cancer-data-veritac/742135/</link><description>Arvinas and Pfizer's partnered breast cancer drug, vepdegestrant, showed promising results in a specific patient subgroup compared to fulvestrant, though it didn't meet overall trial goals. The mixed outcomes highlight the experimental therapy's potential niche benefits while underscoring the challenges of broad efficacy in cancer treatment.</description><pubDate>Tue, 11 Mar 2025 16:45:00 +0000</pubDate></item><item><title>Ascletis’ not-so-great weight loss data; Vivace’s $35M Series D</title><link>https://endpts.com/ascletis-not-so-great-weight-loss-data-vivaces-35m-series-d/</link><description>Harbour BioMed announced a collaboration with Ascletis to develop adipose-targeted obesity therapy ASC47, which recently showed a placebo-adjusted weight loss of only 1.7%, raising concerns about its effectiveness. The partnership aims to leverage Harbour BioMed's expertise in immunotherapy alongside Ascletis' innovation in obesity treatment.</description><pubDate>Wed, 12 Mar 2025 14:22:46 +0000</pubDate></item></channel></rss>